Characterization of recombinant human lactoferrin secreted in milk of transgenic mice

被引:56
作者
Nuijens, JH [1 ]
vanBerkel, PHC [1 ]
Geerts, MEJ [1 ]
Hartevelt, PP [1 ]
deBoer, HA [1 ]
vanVeen, HA [1 ]
Pieper, FR [1 ]
机构
[1] LEIDEN UNIV,MED BIOTECHNOL DEPT,LEIDEN INST CHEM,NL-2333 CA LEIDEN,NETHERLANDS
关键词
D O I
10.1074/jbc.272.13.8802
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human lactoferrin (hLF) is an iron-binding protein involved in host defense against infection and severe inflammation. Transgenic mice were produced harboring either hLF cDNA or genomic hLF sequences fused to regulatory elements of the bovine alpha S-1 casein gene. Recombinant hLF expressed in the milk of transgenic mice (transgenic hLF) was compared with natural (human milk-derived) hLF. Immunological identity of the two forms was shown by double antibody immunoassays and the absence of an anti-hLF antibody response in transgenic mice on hyperimmunization with natural hLF. Mono S cation-exchange chromatography and N-terminal protein sequencing of transgenic and natural hLF revealed identical cationicity and N-terminal sequences. SDS-polyacrylamide gel electrophoresis and absorbance measurements of purified transgenic hLF showed this protein was 90% saturated with iron, whereas natural hLF is only 3% saturated. The pH-mediated release of iron from transgenic hLF was not different from that of iron-saturated natural hLF, Unsaturated transgenic hLF could be completely resaturated upon addition of iron. Slight differences in mobility between transgenic and natural hLF on SDS-polyacrylamide gel electrophoresis were abolished by enzymatic deglycosylation, Binding of transgenic and natural hLF to a range of ligands, including bacterial lipopolysaccharide, heparin, single-stranded DNA, Cibacron blue FG 3A, and lectins, was not different. Based on these observations, we anticipate that (unsaturated) rhLF and natural hLF will exert similar, if not identical, antibacterial and anti inflammatory activity in vivo.
引用
收藏
页码:8802 / 8807
页数:6
相关论文
共 43 条
[1]   STRUCTURE OF HUMAN LACTOFERRIN - CRYSTALLOGRAPHIC STRUCTURE-ANALYSIS AND REFINEMENT AT 2.8-A RESOLUTION [J].
ANDERSON, BF ;
BAKER, HM ;
NORRIS, GE ;
RICE, DW ;
BAKER, EN .
JOURNAL OF MOLECULAR BIOLOGY, 1989, 209 (04) :711-734
[2]   LACTOFERRIN IS A LIPID A-BINDING PROTEIN [J].
APPELMELK, BJ ;
AN, YQ ;
GEERTS, M ;
THIJS, BG ;
DEBOER, HA ;
MACLAREN, D ;
DEGRAAFF, J ;
NUIJENS, JH .
INFECTION AND IMMUNITY, 1994, 62 (06) :2628-2632
[3]   BACTERICIDAL EFFECT FOR HUMAN LACTOFERRIN [J].
ARNOLD, RR ;
COLE, MF ;
MCGHEE, JR .
SCIENCE, 1977, 197 (4300) :263-265
[4]   IDENTIFICATION OF THE BACTERICIDAL DOMAIN OF LACTOFERRIN [J].
BELLAMY, W ;
TAKASE, M ;
YAMAUCHI, K ;
WAKABAYASHI, H ;
KAWASE, K ;
TOMITA, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1121 (1-2) :130-136
[5]   THE EFFECT OF TRYPSIN AND CHYMOTRYPSIN ON THE INVITRO ANTI-MICROBIAL AND IRON-BINDING PROPERTIES OF LACTOFERRIN IN HUMAN-MILK AND BOVINE COLOSTRUM - UNUSUAL RESISTANCE OF HUMAN APOLACTOFERRIN TO PROTEOLYTIC DIGESTION [J].
BRINES, RD ;
BROCK, JH .
BIOCHIMICA ET BIOPHYSICA ACTA, 1983, 759 (03) :229-235
[6]   NEUTROPHIL DE-GRANULATION INHIBITS POTENTIAL HYDROXYL-RADICAL FORMATION - RELATIVE IMPACT OF MYELOPEROXIDASE AND LACTOFERRIN RELEASE ON HYDROXYL-RADICAL PRODUCTION BY IRON-SUPPLEMENTED NEUTROPHILS ASSESSED BY SPIN-TRAPPING TECHNIQUES [J].
BRITIGAN, BE ;
HASSETT, DJ ;
ROSEN, GM ;
HAMILL, DR ;
COHEN, MS .
BIOCHEMICAL JOURNAL, 1989, 264 (02) :447-455
[7]   IRON-BINDING PROTEINS AND INFLUX OF IRON ACROSS THE DUODENAL BRUSH-BORDER - EVIDENCE FOR SPECIFIC LACTOTRANSFERRIN RECEPTORS IN THE HUMAN INTESTINE [J].
COX, TM ;
MAZURIER, J ;
SPIK, G ;
MONTREUIL, J ;
PETERS, TJ .
BIOCHIMICA ET BIOPHYSICA ACTA, 1979, 588 (01) :120-128
[8]  
CROUCH SPM, 1992, BLOOD, V80, P235
[9]   ENHANCEMENT OF THE ACTIVITY OF CEFOTAXIME BY IRON-BINDING PROTEINS [J].
ELLISON, RT ;
LUO, Q ;
RELLER, LB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (03) :479-481
[10]   KILLING OF GRAM-NEGATIVE BACTERIA BY LACTOFERRIN AND LYSOZYME [J].
ELLISON, RT ;
GIEHL, TJ .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (04) :1080-1091